Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

www.portola.com       |     www.andexxa.com

Enter to win one of our amazing door prizes.  Clinical Decision Making is giving away an Apple Watch Series 5 each day.  Visit each vendor and enter for more chances to win.  Only one entry per vendor page is allowed - invalid email address entries and duplicate entries will be deleted before the drawing each day.

Contact Information

Office Location & Contact

Portola Pharmaceuticals Inc.
270 E. Grand Avenue
South San Francisco, CA  94080

Phone: 650.246.7000
Fax: 650.246.7376
Email: contact@portola.com


  • Gregg Wolf
    Thrombosis Area Manager, NE
    Phone: (516) 732-7835
    Email: gwolf@portola.com


Investor Relations


Market Access

  • Elaine Crawford
    Institutional Reimbursement & Access Manager
    Phone: (609) 970-9159
    Email: ecrawford@portola.com

National Accounts

Contact Us

Please enter your name.
Please enter a subject.
Please enter a valid phone number.
Please enter a message.

Our brochures

For more information about Portola:

Visit us on Social Media -